i
Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children
-
Feb 28 2016
Source: J Pediatr. 172:116-120.e1. -
Alternative Title:J Pediatr
-
Publisher's site:
-
Personal Author:
-
Description:Objective
Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care.
Study design
Children were eligible for enrollment if they presented to 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January–June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system (IIS). Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative.
Results
Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n=87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8–23months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively.
Conclusions
Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first two years of life.
-
Subject:
-
Source:
-
Pubmed ID:26935786
-
Pubmed Central ID:PMC5040162
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
[PDF-79.10 KB]
Email
CDC-INFO
